Doxorubicin (Adriamycin) has been used in oncologic practicesince the late 1960s. It held promise as a powerful drug inthe fight against cancer. The tumors most commonly respondingto doxorubicin when it is given as a single agent or in combinationwith other antitumor agents include breast and esophageal carcinomas;osteosarcoma, Kaposi's sarcoma, and soft-tissue sarcomas; andHodgkin's and non-Hodgkin's lymphomas. Other cancers that areless responsive to doxorubicin but that are still treated withthe drug because of its overall benefits include gastric, liver,bile-duct, pancreatic, and endometrial carcinomas. However,reports of fatal cardiotoxic effects of doxorubicin have . . . [Full Text of this Article]
Cause
Diagnosis
Physical Examination
Electrocardiography
Echocardiography and Angiocardiography
Endomyocardial Biopsy
Management
Prevention
Use of Analogues and "Cocktails"
Alternative Approaches to Drug Delivery
Cardioprotective Agents
Treatment
Future Prospects
Conclusions
Source Information
From the Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, and the Department of Physiology, Faculty of Medicine, University of Manitoba, Winnipeg, Man., Canada.
Address reprint requests to Dr. Singal at the Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, 351 Tache Ave., Rm. R3022, Winnipeg, MB R2H 2A6, Canada.
References
Related Letters:
Doxorubicin-Induced Cardiomyopathy
Lipshultz S. E., Grenier M. A., Colan S. D., Ginsburg A. D., Swain S. M., Muggia F. M., Speyer J. L., Singal P. K., Olweny C. L.M., Li T.
Extract |
Full Text
N Engl J Med 1999;
340:653-655, Feb 25, 1999.
Correspondence
This article has been cited by other articles:
Little, G. H., Saw, A., Bai, Y., Dow, J., Marjoram, P., Simkhovich, B., Leeka, J., Kedes, L., Kloner, R. A., Poizat, C.
(2009). Critical Role of Nuclear Calcium/Calmodulin-dependent Protein Kinase II{delta}B in Cardiomyocyte Survival in Cardiomyopathy. J. Biol. Chem.
284: 24857-24868
[Abstract][Full Text]
Takabatake, D., Taira, N., Hara, F., Sien, T., Kiyoto, S., Takashima, S., Aogi, K., Ohsumi, S., Doihara, H., Takashima, S.
(2009). Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. Jpn J Clin Oncol
39: 478-483
[Abstract][Full Text]
Zhang, Y., El-Sikhry, H., Chaudhary, K. R., Batchu, S. N., Shayeganpour, A., Jukar, T. O., Bradbury, J. A., Graves, J. P., DeGraff, L. M., Myers, P., Rouse, D. C., Foley, J., Nyska, A., Zeldin, D. C., Seubert, J. M.
(2009). Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol.
297: H37-H46
[Abstract][Full Text]
Jungsuwadee, P., Nithipongvanitch, R., Chen, Y., Oberley, T. D., Butterfield, D. A., St. Clair, D. K., Vore, M.
(2009). Mrp1 Localization and Function in Cardiac Mitochondria after Doxorubicin. Mol. Pharmacol.
75: 1117-1126
[Abstract][Full Text]
Mukhopadhyay, P., Rajesh, M., Batkai, S., Kashiwaya, Y., Hasko, G., Liaudet, L., Szabo, C., Pacher, P.
(2009). Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol. Heart Circ. Physiol.
296: H1466-H1483
[Abstract][Full Text]
Niu, J., Azfer, A., Wang, K., Wang, X., Kolattukudy, P. E.
(2009). Cardiac-Targeted Expression of Soluble Fas Attenuates Doxorubicin-Induced Cardiotoxicity in Mice. J. Pharmacol. Exp. Ther.
328: 740-748
[Abstract][Full Text]
Hiraumi, Y., Iwai-Kanai, E., Baba, S., Yui, Y., Kamitsuji, Y., Mizushima, Y., Matsubara, H., Watanabe, M., Watanabe, K.-i., Toyokuni, S., Matsubara, H., Nakahata, T., Adachi, S.
(2009). Granulocyte colony-stimulating factor protects cardiac mitochondria in the early phase of cardiac injury. Am. J. Physiol. Heart Circ. Physiol.
296: H823-H832
[Abstract][Full Text]
Ochodnicky, P., Henning, R. H., Buikema, H., Kluppel, A. C. A., van Wattum, M., de Zeeuw, D., van Dokkum, R. P. E.
(2009). Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant
24: 413-420
[Abstract][Full Text]
VILLANI, F., BUSIA, A., VILLANI, M., LAFFRANCHI, A., VIVIANI, S., BONFANTE, V.
(2009). Cardiopulmonary Response to Exercise in Patients with Different Degrees of Lung Toxicity after Radio-chemotherapy for Hodgkin's Disease. Anticancer Res
29: 777-783
[Abstract][Full Text]
Zhu, W., Soonpaa, M. H., Chen, H., Shen, W., Payne, R. M., Liechty, E. A., Caldwell, R. L., Shou, W., Field, L. J.
(2009). Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway. Circulation
119: 99-106
[Abstract][Full Text]
Chua, C. C., Gao, J., Ho, Y.-S., Xu, X., Kuo, I-C., Chua, K.-Y., Wang, H., Hamdy, R. C., Reed, J. C., Chua, B. H.L.
(2009). Over-expression of a modified bifunctional apoptosis regulator protects against cardiac injury and doxorubicin-induced cardiotoxicity in transgenic mice. Cardiovasc Res
81: 20-27
[Abstract][Full Text]
Thiene, G., Valente, M., Lombardi, M., Basso, C.
(2009). CHAPTER 20 Tumours of the Heart. ESC Textbook of Cardiovascular Medicine
2: med-9780199566990-chapter-med-9780199566990-chapter
[Abstract][Full Text]
Armenian, S. H., Sun, C.-L., Francisco, L., Steinberger, J., Kurian, S., Wong, F. L., Sharp, J., Sposto, R., Forman, S. J., Bhatia, S.
(2008). Late Congestive Heart Failure After Hematopoietic Cell Transplantation. JCO
26: 5537-5543
[Abstract][Full Text]
Canzoneri, J. C., Oyelere, A. K.
(2008). Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res
36: 6825-6834
[Abstract][Full Text]
Fan, G.-C., Zhou, X., Wang, X., Song, G., Qian, J., Nicolaou, P., Chen, G., Ren, X., Kranias, E. G.
(2008). Heat Shock Protein 20 Interacting With Phosphorylated Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity. Circ. Res.
103: 1270-1279
[Abstract][Full Text]
Lupertz, R., Chovolou, Y., Unfried, K., Kampkotter, A., Watjen, W., Kahl, R.
(2008). The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-mediated cytotoxicity. Carcinogenesis
29: 2045-2052
[Abstract][Full Text]
Liu, T.-J., Yeh, Y.-C., Ting, C.-T., Lee, W.-L., Wang, L.-C., Lee, H.-W., Wang, K.-Y., Lai, H.-C., Lai, H.-C.
(2008). Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc Res
80: 227-235
[Abstract][Full Text]
Frias, M. A., Somers, S., Gerber-Wicht, C., Opie, L. H., Lecour, S., Lang, U.
(2008). The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis. Cardiovasc Res
80: 69-77
[Abstract][Full Text]
Fang, C., Gu, J., Xie, F., Behr, M., Yang, W., Abel, E. D., Ding, X.
(2008). Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity. Drug Metab. Dispos.
36: 1722-1728
[Abstract][Full Text]
Hershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., Jacobson, J. S.
(2008). Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma. JCO
26: 3159-3165
[Abstract][Full Text]
Takahashi, R. H., Bains, O. S., Pfeifer, T. A., Grigliatti, T. A., Reid, R. E., Riggs, K. W.
(2008). Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro. Drug Metab. Dispos.
36: 991-994
[Abstract][Full Text]
Frei, B. L., Soefje, S. A.
(2008). A Review of the Cardiovascular Effects of Oncology Agents. Journal of Pharmacy Practice
21: 146-158
[Abstract]
Esaki, M., Takemura, G., Kosai, K.-i., Takahashi, T., Miyata, S., Li, L., Goto, K., Maruyama, R., Okada, H., Kanamori, H., Ogino, A., Ushikoshi, H., Minatoguchi, S., Fujiwara, T., Fujiwara, H.
(2008). Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol.
294: H1048-H1057
[Abstract][Full Text]
Shankar, S. M., Marina, N., Hudson, M. M., Hodgson, D. C., Adams, M. J., Landier, W., Bhatia, S., Meeske, K., Chen, M. H., Kinahan, K. E., Steinberger, J., Rosenthal, D.
(2008). Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics
121: e387-e396
[Abstract][Full Text]
Travers, J., Dudgeon, D. J., Amjadi, K., McBride, I., Dillon, K., Laveneziana, P., Ofir, D., Webb, K. A., O'Donnell, D. E.
(2008). Mechanisms of exertional dyspnea in patients with cancer. J. Appl. Physiol.
104: 57-66
[Abstract][Full Text]
Xia, L., Jaafar, L., Cashikar, A., Flores-Rozas, H.
(2007). Identification of Genes Required for Protection from Doxorubicin by a Genome-Wide Screen in Saccharomyces cerevisiae. Cancer Res.
67: 11411-11418
[Abstract][Full Text]
Unger, C., Haring, B., Medinger, M., Drevs, J., Steinbild, S., Kratz, F., Mross, K.
(2007). Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin. Clin. Cancer Res.
13: 4858-4866
[Abstract][Full Text]
Atallah, E., Durand, J.-B., Kantarjian, H., Cortes, J.
(2007). Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood
110: 1233-1237
[Abstract][Full Text]
Mukhopadhyay, P., Batkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Hasko, G., Zsengeller, Z., Gerard, N. P., Liaudet, L., Kunos, G., Pacher, P.
(2007). Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. J Am Coll Cardiol
50: 528-536
[Abstract][Full Text]
Neilan, T. G., Blake, S. L., Ichinose, F., Raher, M. J., Buys, E. S., Jassal, D. S., Furutani, E., Perez-Sanz, T. M., Graveline, A., Janssens, S. P., Picard, M. H., Scherrer-Crosbie, M., Bloch, K. D.
(2007). Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin. Circulation
116: 506-514
[Abstract][Full Text]
Nabhan, C.
(2007). It Is Follicular... . So, Why CHOP?. JCO
25: 915-916
[Full Text]
Boice, J. D. Jr
(2007). An Affair of the Heart. JNCI J Natl Cancer Inst
99: 186-187
[Full Text]
Ito, T., Fujio, Y., Takahashi, K., Azuma, J.
(2007). Degradation of NFAT5, a Transcriptional Regulator of Osmotic Stress-related Genes, Is a Critical Event for Doxorubicin-induced Cytotoxicity in Cardiac Myocytes. J. Biol. Chem.
282: 1152-1160
[Abstract][Full Text]
Kratz, F, Ehling, G, Kauffmann, H-M, Unger, C
(2007). Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol
26: 19-35
[Abstract]
Fujisaka, Y., Horiike, A., Shimizu, T., Yamamoto, N., Yamada, Y., Tamura, T.
(2006). Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors. Jpn J Clin Oncol
36: 768-774
[Abstract][Full Text]
Jungsuwadee, P., Cole, M. P., Sultana, R., Joshi, G., Tangpong, J., Butterfield, D. A., St. Clair, D. K., Vore, M.
(2006). Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.. Molecular Cancer Therapeutics
5: 2851-2860
[Abstract][Full Text]
Christiansen, S., Autschbach, R.
(2006). Doxorubicin in experimental and clinical heart failure.. Eur. J. Cardiothorac. Surg.
30: 611-616
[Abstract][Full Text]
Neilan, T. G., Jassal, D. S., Perez-Sanz, T. M., Raher, M. J., Pradhan, A. D., Buys, E. S., Ichinose, F., Bayne, D. B., Halpern, E. F., Weyman, A. E., Derumeaux, G., Bloch, K. D., Picard, M. H., Scherrer-Crosbie, M.
(2006). Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J
27: 1868-1875
[Abstract][Full Text]
Hamed, S., Barshack, I., Luboshits, G., Wexler, D., Deutsch, V., Keren, G., George, J.
(2006). Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J
27: 1876-1883
[Abstract][Full Text]
Neilan, T. G., Doherty, G. A., Chen, G., Deflandre, C., McAllister, H., Butler, R. K., McClelland, S. E., Kay, E., Ballou, L. R., Fitzgerald, D. J.
(2006). Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am. J. Physiol. Heart Circ. Physiol.
291: H532-H536
[Abstract][Full Text]
Chua, C. C., Liu, X., Gao, J., Hamdy, R. C., Chua, B. H. L.
(2006). Multiple actions of pifithrin-{alpha} on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am. J. Physiol. Heart Circ. Physiol.
290: H2606-H2613
[Abstract][Full Text]
Neilan, T. G., Jassal, D. S., Scully, M. F., Chen, G., Deflandre, C., McAllister, H., Kay, E., Austin, S. C., Halpern, E. F., Harmey, J. H., Fitzgerald, D. J.
(2006). Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J
27: 1251-1256
[Abstract][Full Text]
Lien, Y.-C., Noel, T., Liu, H., Stromberg, A. J., Chen, K.-C., St. Clair, D. K.
(2006). Phospholipase C-{delta}1 Is a Critical Target for Tumor Necrosis Factor Receptor-Mediated Protection against Adriamycin-Induced Cardiac Injury.. Cancer Res.
66: 4329-4338
[Abstract][Full Text]
Yi, X., Bekeredjian, R., DeFilippis, N. J., Siddiquee, Z., Fernandez, E., Shohet, R. V.
(2006). Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol.
290: H1098-H1102
[Abstract][Full Text]
Thorburn, A., Frankel, A. E.
(2006). Apoptosis and anthracycline cardiotoxicity.. Molecular Cancer Therapeutics
5: 197-199
[Full Text]
Lien, Y.-C., Lin, S.-M., Nithipongvanitch, R., Oberley, T. D., Noel, T., Zhao, Q., Daosukho, C., St. Clair, D. K.
(2006). Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection.. Molecular Cancer Therapeutics
5: 261-269
[Abstract][Full Text]
Li, L., Takemura, G., Li, Y., Miyata, S., Esaki, M., Okada, H., Kanamori, H., Khai, N. C., Maruyama, R., Ogino, A., Minatoguchi, S., Fujiwara, T., Fujiwara, H.
(2006). Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy. Circulation
113: 535-543
[Abstract][Full Text]
Fumoleau, P., Roche, H., Kerbrat, P., Bonneterre, J., Romestaing, P., Fargeot, P., Namer, M., Monnier, A., Montcuquet, P., Goudier, M.-J., Luporsi, E., On behalf of the French Adjuvant Study Group,
(2006). Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results. Ann Oncol
17: 85-92
[Abstract][Full Text]
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., Hershman, D. L.
(2005). Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study. JCO
23: 8597-8605
[Abstract][Full Text]
Del Mastro, L., Perrone, F.
(2005). Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. (Ann Oncol 2005; 16: 1979). Ann Oncol
16: 1979-1980
[Full Text]
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., Lenihan, D. J.
(2005). Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. JCO
23: 7820-7826
[Abstract][Full Text]
Simsir, S. A., Lin, S. S., Blue, L. J., Gockerman, J. P., Russell, S. D., Milano, C. A.
(2005). Left Ventricular Assist Device as Destination Therapy in Doxorubicin-Induced Cardiomyopathy. Ann. Thorac. Surg.
80: 717-719
[Abstract][Full Text]
Sandri, M. T., Salvatici, M., Cardinale, D., Zorzino, L., Passerini, R., Lentati, P., Leon, M., Civelli, M., Martinelli, G., Cipolla, C. M.
(2005). N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?. Clin. Chem.
51: 1405-1410
[Abstract][Full Text]
Chicco, A. J., Schneider, C. M., Hayward, R.
(2005). Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am. J. Physiol. Regul. Integr. Comp. Physiol.
289: R424-R431
[Abstract][Full Text]
Hayek, E. R., Speakman, E., Rehmus, E.
(2005). Acute Doxorubicin Cardiotoxicity. NEJM
352: 2456-2457
[Full Text]
Peng, X., Chen, B., Lim, C. C., Sawyer, D. B.
(2005). The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE. Mol. Interv.
5: 163-171
[Abstract][Full Text]
Kilickap, S., Barista, I., Akgul, E., Aytemir, K., Aksoyek, S., Aksoy, S., Celik, I., Kes, S., Tekuzman, G.
(2005). cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol
16: 798-804
[Abstract][Full Text]
Fisher, P. W., Salloum, F., Das, A., Hyder, H., Kukreja, R. C.
(2005). Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity. Circulation
111: 1601-1610
[Abstract][Full Text]
Lou, H., Danelisen, I., Singal, P. K.
(2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol.
288: H1925-H1930
[Abstract][Full Text]
Lakhman, S. S., Ghosh, D., Blanco, J. G.
(2005). FUNCTIONAL SIGNIFICANCE OF A NATURAL ALLELIC VARIANT OF HUMAN CARBONYL REDUCTASE 3 (CBR3). Drug Metab. Dispos.
33: 254-257
[Abstract][Full Text]
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., Mellars, L., Alland, L., Tendler, C.
(2004). Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer. JCO
22: 3893-3901
[Abstract][Full Text]
Lillig, C. H., Lonn, M. E., Enoksson, M., Fernandes, A. P., Holmgren, A.
(2004). Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc. Natl. Acad. Sci. USA
101: 13227-13232
[Abstract][Full Text]
Bonneterre, J., Roche, H., Kerbrat, P., Fumoleau, P., Goudier, M.-J., Fargeot, P., Montcuquet, P., Clavere, P., Barats, J.-C., Monnier, A., Veyret, C., Datchary, J., Van Praagh, I., Chapelle-Marcillac, I.
(2004). Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group. JCO
22: 3070-3079
[Abstract][Full Text]
Wang, S., Konorev, E. A., Kotamraju, S., Joseph, J., Kalivendi, S., Kalyanaraman, B.
(2004). Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms: INTERMEDIACY OF H2O2- AND p53-DEPENDENT PATHWAYS. J. Biol. Chem.
279: 25535-25543
[Abstract][Full Text]
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L.
(2004). Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol. Rev.
56: 185-229
[Abstract][Full Text]
Simunek, T., Klimtova, I., Kaplanova, J., Mazurova, Y., Adamcova, M., Sterba, M., Hrdina, R., Gersl, V.
(2004). Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail
6: 377-387
[Abstract][Full Text]
Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., Nemer, M.
(2004). Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA
101: 6975-6980
[Abstract][Full Text]
Yan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., Engelhardt, J. F.
(2004). Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia. J. Virol.
78: 2863-2874
[Abstract][Full Text]
Cresta, S., Grasselli, G., Mansutti, M., Martoni, A., Lelli, G., Capri, G., Buzzi, F., Robustelli Della Cuna, G., Jirillo, A., Terzoli, E., Frevola, L., Tarenzi, E., Sguotti, C., Azli, N., Murawsky, M., Gianni, L.
(2004). A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol
15: 433-439
[Abstract][Full Text]
O'Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., Orlandi, F., Mellars, L., Alland, L., Tendler, C.
(2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil(R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol
15: 440-449
[Abstract][Full Text]
Torrado, M., Lopez, E., Centeno, A., Castro-Beiras, A., Mikhailov, A. T.
(2004). Left-right asymmetric ventricular expression of CARP in the piglet heart: regional response to experimental heart failure. Eur J Heart Fail
6: 161-172
[Abstract][Full Text]
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., Hirsh, V.
(2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol
15: 19-27
[Abstract][Full Text]
Bianchi, G., Albanell, J., Eiermann, W., Vitali, G., Borquez, D., Vigano, L., Molina, R., Raab, G., Locatelli, A., Vanhauwere, B., Gianni, L., Baselga, J.
(2003). Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer. Clin. Cancer Res.
9: 5944-5951
[Abstract][Full Text]
Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J., Walker, U. A.
(2003). Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy. Circulation
108: 2423-2429
[Abstract][Full Text]
Olson, L. E., Bedja, D., Alvey, S. J., Cardounel, A. J., Gabrielson, K. L., Reeves, R. H.
(2003). Protection from Doxorubicin-Induced Cardiac Toxicity in Mice with a Null Allele of Carbonyl Reductase 1. Cancer Res.
63: 6602-6606
[Abstract][Full Text]
Miranda, C. J., Makui, H., Soares, R. J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N. C., Santos, M. M.
(2003). Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood
102: 2574-2580
[Abstract][Full Text]
Swift, L., McHowat, J., Sarvazyan, N.
(2003). Inhibition of Membrane-associated Calcium-independent Phospholipase A2 as a Potential Culprit of Anthracycline Cardiotoxicity. Cancer Res.
63: 5992-5998
[Abstract][Full Text]
Navari, R. M, Koeller, J. M
(2003). Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists. The Annals of Pharmacotherapy
37: 1276-1286
[Abstract][Full Text]
Not, T., Faleschini, E., Tommasini, A., Repetto, A., Pasotti, M., Baldas, V., Spano, A., Sblattero, D., Marzari, R., Campana, C., Gavazzi, A., Tavazzi, L., Biagi, F., Roberto Corazza, G., Ventura, A., Arbustini, E.
(2003). Celiac disease in patients with sporadic and inherited cardiomyopathies and in their relatives. Eur Heart J
24: 1455-1461
[Abstract][Full Text]
Heon, S., Bernier, M., Servant, N., Dostanic, S., Wang, C., Kirby, G. M., Alpert, L., Chalifour, L. E.
(2003). Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Am. J. Physiol. Heart Circ. Physiol.
285: H499-H506
[Abstract][Full Text]
Poutanen, T., Tikanoja, T., Riikonen, P., Silvast, A., Perkkio, M.
(2003). Long-Term Prospective Follow-Up Study of Cardiac Function After Cardiotoxic Therapy for Malignancy in Children. JCO
21: 2349-2356
[Abstract][Full Text]
Balachandar, A V, Malarkodi, K P, Varalakshmi, P
(2003). Protective role of DLa-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol
22: 249-254
[Abstract]
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virag, L., Deb, A., Szabo, E., Ungvari, Z., Wolin, M. S., Groves, J. T., Szabo, C.
(2003). Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction. Circulation
107: 896-904
[Abstract][Full Text]
Limat, S., Demesmay, K., Voillat, L., Bernard, Y., Deconinck, E., Brion, A., Sabbah, A., Woronoff-Lemsi, M. C., Cahn, J. Y.
(2003). Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol
14: 277-281
[Abstract][Full Text]
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., Suzuki, Y. J.
(2003). Anthracycline-Induced Suppression of GATA-4 Transcription Factor: Implication in the Regulation of Cardiac Myocyte Apoptosis. Mol. Pharmacol.
63: 368-377
[Abstract][Full Text]
Nitobe, J., Yamaguchi, S., Okuyama, M., Nozaki, N., Sata, M., Miyamoto, T., Takeishi, Y., Kubota, I., Tomoike, H.
(2003). Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res
57: 119-128
[Abstract][Full Text]
Shioji, K., Kishimoto, C., Nakamura, H., Masutani, H., Yuan, Z., Oka, S.-i., Yodoi, J.
(2002). Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity. Circulation
106: 1403-1409
[Abstract][Full Text]
Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T., Leeuwenburgh, C.
(2002). Doxorubicin Treatment in Vivo Causes Cytochrome c Release and Cardiomyocyte Apoptosis, As Well As Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio. Cancer Res.
62: 4592-4598
[Abstract][Full Text]
Suter, T. M., Meier, B.
(2002). Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?. Ann Oncol
13: 647-649
[Full Text]
Jensen, B. V., Skovsgaard, T., Nielsen, S. L.
(2002). Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol
13: 699-709
[Abstract][Full Text]
Bash-Babula, J., Toppmeyer, D., Labassi, M., Reidy, J., Orlick, M., Senzon, R., Alli, E., Kearney, T., August, D., Shih, W., Yang, J.-M., Hait, W. N.
(2002). A Phase I/Pilot Study of Sequential Doxorubicin/Vinorelbine: Effects on p53 and Microtubule-associated Protein 4. Clin. Cancer Res.
8: 1057-1064
[Abstract][Full Text]
Previous
